Welcome to our dedicated page for Concord Medical SEC filings (Ticker: CCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Proton-therapy build-outs, multi-year lease obligations on linear accelerators, and fast-moving joint-venture agreements make Concord Medical’s disclosures uniquely dense. If you have ever searched “Concord Medical SEC filings explained simply,” you know the challenge of tracking oncology revenue or capital equipment commitments across hundreds of pages. Stock Titan’s AI turns those technical cancer-care details into clear language, highlighting risk factors and segment trends before you finish your coffee.
Every document filed to EDGAR appears here in seconds and is paired with an AI summary that answers the questions investors actually ask—What’s in the Concord Medical annual report 10-K simplified? or Where is the Concord Medical quarterly earnings report 10-Q filing? Drill straight into:
- Concord Medical insider trading Form 4 transactions with instant context
- Concord Medical Form 4 insider transactions real-time alerts on executive moves
- Concord Medical proxy statement executive compensation breakdowns
- Concord Medical 8-K material events explained the moment they post
Need deeper insight? Our platform layers Concord Medical earnings report filing analysis onto KPI dashboards, helping you compare margin shifts across treatment centers and monitor cash spent on new proton systems. Understanding Concord Medical SEC documents with AI means no more manual hunting for equipment depreciation tables or disclosure of related-party leases. Whether you’re reviewing Concord Medical executive stock transactions Form 4 before a financing round or scanning footnotes for regulatory approvals, this page keeps you updated, informed, and ahead of the market.
Concord Medical Services Holdings Ltd. (NYSE: CCM) has filed a Form 6-K to disclose that its Hong Kong–listed subsidiary, Concord Healthcare Group Co., Ltd. (HKSE: 2453.HK), signed a placing agreement on 22 July 2025 with Guotai Junan Securities (Hong Kong). Under the agreement the placing agent will, on a best-effort basis, place 48,723,600 new H-shares with at least six independent investors at HK$5.54 per share. The issuance will be made under Concord Healthcare’s existing general mandate. No financial statements, earnings figures or projected proceeds were provided in the filing.
The transaction increases Concord Healthcare’s share count and is intended to raise fresh capital for the subsidiary; however, the filing does not state the specific use of proceeds or anticipated dilution for Concord Medical’s shareholders. The parent reiterates that additional details on the subsidiary’s Hong Kong transactions can be found on the HKEX website.
Concord Medical Services Holdings Limited (NYSE: CCM) filed a Form 6-K to disclose that its Hong Kong–listed subsidiary, Concord Healthcare Group Co., Ltd. (HKSE: 2453.HK), experienced a reduction in the stake held by one of its controlling shareholders. On 20 June 2025, Beijing Concord Medical Technology Co., Ltd. sold 32,800,000 H shares of Concord Healthcare via block trade at HK$6.12 per share, equal to approximately 4.46 % of Concord Healthcare’s issued share capital. The filing reiterates that Concord Healthcare’s H shares were listed on the HKSE on 9 January 2024 and directs investors to the HKSE website for transaction details.
No additional financial results, earnings data or strategic initiatives were reported in this 6-K.
FAQ
What is the current stock price of Concord Medical (CCM)?
What is the market cap of Concord Medical (CCM)?
